Skip to Main content Skip to Navigation
Master Thesis

Évaluation de l’approche LAIP/LSC (Leukemia Associated ImmunoPhenotype/Leukemic Stem Cells) au diagnostic et au suivi des leucémies aiguës myéloïdes chez l’adulte

Abstract : Currently, many patients with acute myeloid leukemia (AML) relapse after treatment. Monitoring minimal residual disease (MRD) is essential for the evaluation of the efficacy of therapies and for the prognosis, but lack of standardization in flow cytometry (CMF). Today, the LAIP/DfN approach aims to track blasts with the Leukemia Associated ImmunoPhenotype (LAIP) while the more innovative LSC approach aims to assess the presence of leukemic stem cells (LSC) in the immature myeloid compartment CD34+/CD38-. These LSCs are stated to be the cause of relapses. This prospective study from January 2020 to September 2020 including patients with AML at the CHU of Caen proposes a robust and reproducible CMF analysis strategy for these two approaches allowed by the panel of LSC antibodies currently evaluated in several centres in France by the MRD CMF LAM LSC group. Concrete examples of patients illustrate and validate the relevance of the evaluation by CMF of MRD using this double approach combining LAIP and LSC. Due to the small size of the study, this strategy needs to be evaluated on a larger scale but offers good prospects for the monitoring and management of patients with AML.
Document type :
Master Thesis
Complete list of metadata

https://dumas.ccsd.cnrs.fr/dumas-03428311
Contributor : Ufr Santé Unicaen Connect in order to contact the contributor
Submitted on : Monday, November 15, 2021 - 10:05:19 AM
Last modification on : Wednesday, December 1, 2021 - 3:39:53 AM

File

DROGUET-flora.pdf
Files produced by the author(s)

Identifiers

  • HAL Id : dumas-03428311, version 1

Citation

Flora Droguet. Évaluation de l’approche LAIP/LSC (Leukemia Associated ImmunoPhenotype/Leukemic Stem Cells) au diagnostic et au suivi des leucémies aiguës myéloïdes chez l’adulte. Sciences pharmaceutiques. 2020. ⟨dumas-03428311⟩

Share

Metrics

Les métriques sont temporairement indisponibles